EUCTR2012-001245-40-IT
Active, not recruiting
Not Applicable
CLINICAL AND PHARMACOKINETICS STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®)
Not provided0 sitesMay 17, 2013
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Not provided
- Status
- Active, not recruiting
- Last Updated
- 10 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Population: 60 out\-patients with a diagnosis of idiopathic Parkinson's disease for at least 5 years, receiving L\-dopa, will be enrolled to participate into the study. The study will be performed in hospital setting using the facilities of the clinical trial centre in both sites involved in the study. The patients will be recruited within the patient population using the hospitals out\-patients clinics. Recruitment timing will be 12 months.
- •Inclusion Criteria:
- •° Subject must be \>\=30 and \<\=75 years of age, of either sex and of any race.
- •° Diagnosis of Parkinson's disease
- •° Subjects must be in Hoehn and Yahr stages 2 to 4\.
- •° Subject must have good response to levodopa (\>\=30% improvement in the UPDRS score).
- •° Subject must have been on a stable regimen of L\-dopa for at least 4 month before Screening.
- •° A female subject must be postmenopausal, or sterile or use a medically accepted method of contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
Exclusion Criteria
- •° Atypical Parkinsonism
- •° Subjects with very severe motor fluctuations and/or dyskinesias.
- •° Significant internal\-medicine or psychiatric diseases.
- •° Subject's clinical laboratory tests outside the normal ranges.
- •° History of previous rabdomiolysis.
- •° Subjects in therapy with COMT\-inhibitor.
- •° Subjects who participated in any other clinical trial in the 4 months before the screening.
- •° Any subject who is pregnant or breastfeeding.
- •° Subjects demented or not able to give informed consent to trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Study to evaluate the efficacy, metabolism and safety of human immuneglobulin in patients with primary immunodeficiency diseasesprimary immunodeficiency disease (PID)MedDRA version: 14.1Level: LLTClassification code 10049485Term: Bruton's agammaglobulinemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencySystem Organ Class: 10021428 - Immune system disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2012-000792-16-HUOCTAPHARMA AG23
Active, not recruiting
Not Applicable
Study to evaluate the efficacy, metabolism and safety of human immuneglobulin in patients with primary immunodeficiency diseasesprimary immunodeficiency disease (PID)MedDRA version: 14.1Level: LLTClassification code 10049485Term: Bruton's agammaglobulinemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencySystem Organ Class: 10021428 - Immune system disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2012-000792-16-CZOCTAPHARMA AG23
Active, not recruiting
Not Applicable
Study to evaluate the efficacy, metabolism and safety of human immuneglobulin in patients with primary immunodeficiency diseasesEUCTR2012-000792-16-DEOCTAPHARMA AG23
Recruiting
Not Applicable
Clinical pharmacology study to evaluate the pharmacokinetics, safety and efficacy of multi-targetted tyrosine kinase inhibitor regorafenib in Japanese patients with advanced colorectal cancer.Colorectal CancerJPRN-UMIN000013939Showa University School of Medicine100
Active, not recruiting
Phase 1
A CLINICAL PHARMACOLOGY STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF NXT007 WITH A NEW PREPARATION METHOD IN HEALTHY JAPANESE MALE ADULTSJPRN-jRCT2031220050Takehiko Sambe30